AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02223065
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
Phase 2
Completed
- Conditions
- Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT02214121
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 86
- Registration Number
- NCT02209766
- Locations
- 🇯🇵
CPC Clinical Trial Hospital, Kagoshima, Japan
An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients
Completed
- Conditions
- Diabetes
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT02208921
- Locations
- 🇮🇳
Research Site, Trivandrum, India
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT02207530
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Forxiga Tablets Specific Clinical Experience Investigation for Elderly
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1724
- Registration Number
- NCT02200627
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7793
- Registration Number
- NCT02200666
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Procedure: Pharmacokinetic sampling - AZD9291Drug: AZD9291 tablet dosingProcedure: Pharmacokinetic sampling - simvastatinProcedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT02197234
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Procedure: Pharmacokinetic sampling - AZD9291Drug: AZD9291 tablet dosingProcedure: Pharmacokinetic sampling - rifampicinProcedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT02197247
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
Phase 3
Completed
- Conditions
- Uncontrolled Asthma
- Interventions
- Other: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 856
- Registration Number
- NCT02194699
- Locations
- 🇬🇧
Research Site, Wishaw, United Kingdom